Oveporexton previously received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in NT1 from the U.S. FDA and the Center for Drug Evaluation of China’s National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results